A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Clinical trial NCT06446128 · RECRUITING
Trial details
- NCT number
- NCT06446128
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-07
- Primary completion
- 2026-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.